Detail akcie Matinas Bio Rg online

Business Summary: Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Matinas BioPharma Holdings Inc revenues was not reported. Net loss decreased 47% to $8.4M. Lower net loss reflects Stock-based Compensation in R&D decrease of 93% to $85K (expense), Stock-based Compensation in SGA decrease of 59% to $721K (expense), General and administrative - Balancing decrease of 15% to $4.6M (expense).